Literature DB >> 6629320

Determinants of drug disposition in patients with cirrhosis.

P M Huet, J P Villeneuve.   

Abstract

The effects of alterations of the hepatic blood flow, the intrinsic clearance, and the anatomy of the portal circulation on drug disposition were investigated in 53 cirrhotic patients with portal hypertension using indocyanine green (ICG) and lidocaine as model drugs. ICG disposition was studied by sampling from an artery and one hepatic vein following i.v. injection, with determination of systemic and intrinsic clearances and hepatic blood flow. Lidocaine disposition was studied following i.v. and oral administration from peripheral vein disappearance curves, with determination of systemic and intrinsic clearances and systemic availability. The shunted fraction of intestinal blood flow (f) was measured from the combined ICG and lidocaine disposition studies. In the 53 patients, systemic clearances of ICG and lidocaine varied widely and were significantly correlated with each other (r = 0.725, p less than 0.001). The systemic clearances of both ICG and lidocaine were not related to hepatic blood flow but were significantly correlated to their respective intrinsic clearances (for ICG: r = 0.948, p less than 0.001; for lidocaine: r = 0.873, p less than 0.001). Lidocaine systemic availability was also found to vary widely from 0.2 to 1.0. In 28 patients, f was less than 0.1 indicating minimal extrahepatic shunting and in these patients, lidocaine systemic availability was related to its intrinsic clearance (r = -0.717, p less than 0.001); in the 25 other patients with significant extrahepatic shunting (f greater than 0.1), the extent of lidocaine systemic availability was related to both intrinsic clearance (r = -0.819, p less than 0.001) and extrahepatic shunting (r = 0.913, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6629320     DOI: 10.1002/hep.1840030604

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  25 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 4.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

5.  Stability of cirrhotic systemic hemodynamics ensures sufficient splanchnic blood flow after living-donor liver transplantation in adult recipients with liver cirrhosis.

Authors:  Tomohide Hori; Shintaro Yagi; Taku Iida; Kentaro Taniguchi; Kentaro Yamagiwa; Chiduru Yamamoto; Takashi Hasegawa; Koichiro Yamakado; Takuma Kato; Kanako Saito; Linan Wang; Mie Torii; Yukinobu Hori; Kan Takeda; Kazuo Maruyama; Shinji Uemoto
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Hepatic microcirculation in the perfused cirrhotic rat liver.

Authors:  F Varin; P M Huet
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

Review 7.  Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation.

Authors:  Tomohide Hori; Yasuhiro Ogura; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Motoshi Kainuma; Hideo Takahashi; Shogo Suzuki; Takashi Ichikawa; Shoko Mizuno; Tadashi Aoyama; Yuki Ishida; Takahiro Hirai; Tomoko Hayashi; Kazuko Hasegawa; Hiromu Takeichi; Atsunobu Ota; Yasuhiro Kodera; Hiroyuki Sugimoto; Taku Iida; Shintaro Yagi; Kentaro Taniguchi; Shinji Uemoto
Journal:  World J Hepatol       Date:  2016-09-08

8.  Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.

Authors:  Rocco Orlando; Pierpaolo Piccoli; Sara De Martin; Roberto Padrini; Pietro Palatini
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 9.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

10.  Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.

Authors:  M Bührer; J Y Le Cotonnec; M Wermeille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.